rabbit anti human proliferating cell nuclear antigen pcna  (Boster Bio)

Journal: Oncologie

Article Title: Forkhead Box P4 promotes the proliferation of cells in colorectal adenocarcinoma

doi: 10.1515/oncologie-2023-0009

Figure Lengend Snippet: Figure 2: Correlation of FOXP4 and PCNA in CRAC.

Article Snippet: Rabbit anti-humanFOXP4 (16772-1-AP)wasprocured from Wuhan proteintech (Wuhan, China), and rabbit anti-human proliferating cell nuclear antigen (PCNA) (A00125) was procured from Wuhan Boster Biological Technology (Wuhan, China).

Techniques:

Journal: Experimental and Therapeutic Medicine

Article Title: Emodin inhibits the proliferation of papillary thyroid carcinoma by activating AMPK

doi: 10.3892/etm.2021.10509

Figure Lengend Snippet: Emodin decreased the expression of PCNA, Cyclin D1, increased the expression of Cleaved-caspase-3, p-AMPK/AMPK in TPC-1 cells. (A) Western blot analysis to detect PCNA, Cyclin D1 and Cleaved-caspase-3/caspase-3; (B) Western blot analysis to detect p-AMPK/AMPK protein expression. Data are presented as mean ± standard deviation and analyzed by ANOVA. There were three parallel samples in each group. * P<0.05, ** P<0.01 vs. control. PCNA, proliferating cell nuclear antigen; p, phosphorylated.

Article Snippet: The primary antibodies used were as follows: Rabbit anti-human proliferating cell nuclear antigen (PCNA) antibody (1:700; cat. no. orb386383; Biorbyt, Ltd.), anti-Cleaved caspase-3 antibody (1:500; cat. no. ab49822; Abcam), caspase-3 antibody (1:500; cat. no. ab13847; Abcam), anti-Cyclin D1 antibody (1:200; cat. no. ab16663; Abcam), anti-phosphorylated (p-)AMPKa1 (Thr172) Antibody (1:1,000; cat. no. orb99303; Biorbyt, Ltd.), anti-AMPKa1 Antibody (1:1,000; cat. no. orb338932; Biorbyt, Ltd.), anti-ERK1/2 antibody (1:600; cat. no. orb106403; Biorbyt, Ltd.), anti-p-ERK1/2 antibody (1:600; Biorbyt, Ltd.), anti-MEK antibody (1:600; cat. no. orb38774; Biorbyt, Ltd.), anti-p-MEK antibody (1:600; cat. no. orb106207; Biorbyt, Ltd.) and GAPDH antibody (1:8,000; cat. no. orb555879; Biorbyt, Ltd.).

Techniques: Expressing, Western Blot, Standard Deviation, Control

Journal: Experimental and Therapeutic Medicine

Article Title: Emodin inhibits the proliferation of papillary thyroid carcinoma by activating AMPK

doi: 10.3892/etm.2021.10509

Figure Lengend Snippet: Emodin activates AMPK to affect the MEK-ERK pathway in TPC-1 cells. (A) Western blot analysis to detect PCNA, Cyclin D1, Cleaved-caspase-3/caspase-3, p-AMPK and AMPK proteins expression. (B) Western blot to detect p-MEK/MEK, p-ERK1/2/ERK1/2 proteins expression. GAPDH was used as the internal control. Data are presented as mean ± standard deviation and analyzed by ANOVA. There were three parallel samples in each group. * P<0.05 vs. control group, # P<0.05 vs. emodin group; & P<0.05 vs. AICAR group. PCNA, proliferating cell nuclear antigen; p, phosphorylated.

Article Snippet: The primary antibodies used were as follows: Rabbit anti-human proliferating cell nuclear antigen (PCNA) antibody (1:700; cat. no. orb386383; Biorbyt, Ltd.), anti-Cleaved caspase-3 antibody (1:500; cat. no. ab49822; Abcam), caspase-3 antibody (1:500; cat. no. ab13847; Abcam), anti-Cyclin D1 antibody (1:200; cat. no. ab16663; Abcam), anti-phosphorylated (p-)AMPKa1 (Thr172) Antibody (1:1,000; cat. no. orb99303; Biorbyt, Ltd.), anti-AMPKa1 Antibody (1:1,000; cat. no. orb338932; Biorbyt, Ltd.), anti-ERK1/2 antibody (1:600; cat. no. orb106403; Biorbyt, Ltd.), anti-p-ERK1/2 antibody (1:600; Biorbyt, Ltd.), anti-MEK antibody (1:600; cat. no. orb38774; Biorbyt, Ltd.), anti-p-MEK antibody (1:600; cat. no. orb106207; Biorbyt, Ltd.) and GAPDH antibody (1:8,000; cat. no. orb555879; Biorbyt, Ltd.).

Techniques: Western Blot, Expressing, Control, Standard Deviation

Journal: Experimental and Therapeutic Medicine

Article Title: Emodin inhibits the proliferation of papillary thyroid carcinoma by activating AMPK

doi: 10.3892/etm.2021.10509

Figure Lengend Snippet: Emodin activates AMPK to suppress the MEK-ERK pathway in vivo . (A) Western blot analysis to detect PCNA, Cyclin D1, Cleaved-caspase-3/caspase-3 and p-AMPK/AMPK proteins expression. (B) Western blot analysis to detect p-MEK/MEK, p-ERK1/2/ERK1/2 protein expression. Data are presented as mean ± standard deviation and analyzed by ANOVA. There were six mice in each group. The Combine group comprised cells treated with emodin and dorsomorphin. ^ P<0.05 vs. model group; # P<0.05 vs. emodin group; & P<0.05 vs. AICAR group. PCNA, proliferating cell nuclear antigen; p, phosphorylated.

Article Snippet: The primary antibodies used were as follows: Rabbit anti-human proliferating cell nuclear antigen (PCNA) antibody (1:700; cat. no. orb386383; Biorbyt, Ltd.), anti-Cleaved caspase-3 antibody (1:500; cat. no. ab49822; Abcam), caspase-3 antibody (1:500; cat. no. ab13847; Abcam), anti-Cyclin D1 antibody (1:200; cat. no. ab16663; Abcam), anti-phosphorylated (p-)AMPKa1 (Thr172) Antibody (1:1,000; cat. no. orb99303; Biorbyt, Ltd.), anti-AMPKa1 Antibody (1:1,000; cat. no. orb338932; Biorbyt, Ltd.), anti-ERK1/2 antibody (1:600; cat. no. orb106403; Biorbyt, Ltd.), anti-p-ERK1/2 antibody (1:600; Biorbyt, Ltd.), anti-MEK antibody (1:600; cat. no. orb38774; Biorbyt, Ltd.), anti-p-MEK antibody (1:600; cat. no. orb106207; Biorbyt, Ltd.) and GAPDH antibody (1:8,000; cat. no. orb555879; Biorbyt, Ltd.).

Techniques: In Vivo, Western Blot, Expressing, Standard Deviation

Journal: Molecular medicine reports

Article Title: CXC195 induces apoptosis and endoplastic reticulum stress in human hepatocellular carcinoma cells by inhibiting the PI3K/Akt/mTOR signaling pathway.

doi: 10.3892/mmr.2015.4479

Figure Lengend Snippet: Figure 2. Effects of CXC195 on the proliferation of HepG2 cells. (A) Cell cycle distribution was examined using flow cytometry. (B and C) Protein expres sion levels of PCNA, Ki67, CDK4, cyclin D1, p21, p27 and p53 were determined using western blot analysis. GAPDH was used to confirm equal protein loading. Data are presented as the mean ± standard deviation (n=6). *P<0.05 and **P<0.01, vs. control. PCNA, proliferating cell nuclear antigen; CDK4, cyclin‑dependent kinase 4; Con, control.

Article Snippet: The membrane was blocked with 5% skimmed milk and incubated with PBS containing Tween 20 and the following primary antibodies at 1:500 dilution: Monoclonal/polyclonal mouse/rabbit anti-human proliferating cell nuclear antigen (PCNA) (cat no. sc-25280), p21 (sc-397), p27 (sc-393380), p53 (sc-126), Bcl-2 (sc-7382), Bcl-2-associated X (Bax) (sc-7480), AIF (sc-13116), Cyt-c (sc-13561), cyclooxygenase (COX)4 (sc-292052), tubulin (sc-9104), histone (sc-10806), glucose‐regulated protein (GRP)94 (sc-11402), GRP78 (sc-1050), CCAAT-enhancer-binding protein homologous protein (CHOP) (sc-575) and GAPDH (sc-365062) (Santa Cruz Biotechnology, Dallas, TX, USA) and cyclin-dependend kinase (CDK)4 (cat no. 12790), cyclin D1 (1044), phosphorylated (p)-PERK (3179), PERK (3192), eIF2α (9722), p-eIF2α (3597), ATF4 (11815), IRE1α (3294), p-ASK (3765), ASK (37626S), p-p38 (4511), p38 (9213), ATF6 (11815S), p-PI3K (4288S), PI3K (4249S), p-AKT (4060P), AKT (#2920S), mammalian target of rapamycin (mTOR) (2983S) and p-mTOR (5536S) (Cell Signaling Technology, Inc., Danvers, MA, USA) overnight at 4 ̊C.

Techniques: Flow Cytometry, Western Blot, Standard Deviation, Control